health
STAT+: EU and US advisers split over AstraZeneca breast cancer drug
Why this matters: health reporting relevant to everyday decisions and well-being.
Want to stay on top of the science and politics driving biotech today?&#x A0;Sign up&#x A0;to get our biotech newsletter in your inbox. Merck’s bet on an antibody-drug conjugate developed in China has paid off in a major Phase 3 lung cancer study, where sacituzumab tirumotecan paired with Keytruda sharply outperformed Keytruda alone in a subset of lung cancer patients. Also, the NIH is down another leader, and Sam Altman-backed longevity startup Retro Biosciences raises more funds.Continue to STAT+ to read the full story…
Article preview — originally published by STAT News. Full story at the source.
Read full story on STAT News →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from STAT News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop